Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2026-01-04 @ 8:58 AM
Study NCT ID:
NCT05460767
Status:
RECRUITING
Last Update Posted:
2023-12-29
First Post:
2022-07-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-31
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-07-05
First Submit QC Date:
None
Study First Post Date:
2022-07-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-24
Last Update Post Date:
2023-12-29
Last Update Post Date Type:
ACTUAL